Zoetis earns license for Cytopoint skin therapyJanuary 4, 2017Veterinary drug maker Zoetis Inc. in December received a U.S. Department of Agriculture license for Cytopoint, which the Parsippany, N.J., company described as the first monoclonal antibody (mAb) therapy approved βto help provide sustained control of the clinical signs associated with atopic dermatitis in dogs.β
SPONSORED CONTENTTake Control With ProHeart 12 (moxidectin)One dose offers year-long protection with a single injection, putting compliance in your hands. + Learn more